{
    "nct_id": "NCT05231746",
    "official_title": "A Phase 1, Multicenter, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of hSTC810 Monotherapy in Subjects With Advanced Solid Tumors",
    "inclusion_criteria": "* Male or female aged at 18 ≥ years\n* Capable and willing to give signed informed consent\n* At least one measurable lesion as determined by RECIST Ver.1.1\n* ECOG PS score ≤ 1\n* Expected survival ≥ 12 weeks\n* For female or male patients of reproductive potential: Agree to use contraception throughout the study and at least 6 months after the last dose.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subject who has received anti-cancer treatment within 4 weeks prior to the first dose of study treatment.\n* Subject who has received radiotherapy or major surgery within 4 weeks prior to screening.\n* Any toxicity due to prior therapy that has not resolved to ≤ Grade 1 or returned to baseline by the time of starting study treatment.\n* Subject with known severe (≥Grade 3) hypersensitivity to any checkpoint inhibitor.\n* Clinically significant laboratory abnormalities.\n* Subject with a history of another invasive malignancy within 3 years before the first dose of study drug.\n* Subject with active central nervous system (CNS) metastases.\n* Subject who requires high dose of steroids or other immunosuppressive medications.\n* Subject with a history of autoimmune disease that has required systemic treatment in the past 2 years.\n* Subject with active infection that requires systemic antimicrobial treatment.\n* Subject with active HBV or HCV infection.\n* Subject who has a known history of HIV infection.\n* Subject with active tuberculosis.\n* Subject with a documented history of a cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms consistent with NYHA Class IV within 6 months prior to screening.\n* Subject with a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening CT scan.\n* Subject who has received a prior allogeneic stem cell or solid organ transplant.\n* Subject with a positive coronavirus disease (COVID) test during screening.\n* Subjects who have received a live attenuated vaccine within 30 days prior to screening.\n* Subject with another underlying medical condition.",
    "miscellaneous_criteria": ""
}